Listed

Colgate Palmolive Co: Form 10-Q for the period ended Jun 30, 2023

Filed with the SEC on Jul 28, 2023 and accepted by EDGAR at Jul 28, 2023, 08:06 ET.

Share

Management's discussion and analysis

As filed, 1,961 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

On March 10, 2022, the Board authorized the repurchase of shares of the Company’s common stock having an aggregate purchase price of up to $5 billion under a new share repurchase program (the “2022 Program”), which replaced a previously authorized share repurchase program. The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Company’s compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Company’s discretion, subject to market conditions, customary blackout periods and other factors.

The following table shows the stock repurchase activity for the three months in the quarter ended June 30, 2023:

Month Total Number of Shares Purchased(1) Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs(3) (in millions)
April 1 through 30, 2023 900,774 $76.29 899,961 $3,729
May 1 through 31, 2023 1,548,760 $78.95 1,546,900 $3,607
June 1 through 30, 2023 2,357,602 $76.23 2,356,800 $3,427
Total 4,807,136 $77.12 4,803,661

(1) Includes share repurchases under the 2022 Program and those associated with certain employee elections under the Company’s compensation and benefit programs.

(2) The difference between the total number of shares purchased and the total number of shares purchased as part of publicly announced plans or programs is 3,475 shares, which represents shares deemed surrendered to the Company to satisfy certain employee elections under the Company’s compensation and benefit programs.

(3) Includes approximate dollar value of shares that were available to be purchased under the publicly announced plans or programs that were in effect as of June 30, 2023.

Risk factors

As filed, 186 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes from the risk factors disclosed in “Risk Factors” in Part 1, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-04-01 to 2023-06-30$4.82bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2023-01-01 to 2023-06-30$9.59bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-04-01 to 2023-06-30$2.04bnus-gaap:CostOfRevenue
Cost of revenue6 months2023-01-01 to 2023-06-30$4.09bnus-gaap:CostOfRevenue
Gross profit3 months2023-04-01 to 2023-06-30$2.79bnus-gaap:GrossProfit
Gross profit6 months2023-01-01 to 2023-06-30$5.50bnus-gaap:GrossProfit
Selling, general and administrative3 months2023-04-01 to 2023-06-30$1.77bnus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2023-01-01 to 2023-06-30$3.53bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-04-01 to 2023-06-30$974.0mus-gaap:OperatingIncomeLoss
Operating income6 months2023-01-01 to 2023-06-30$1.88bnus-gaap:OperatingIncomeLoss
Income tax3 months2023-04-01 to 2023-06-30$353.0mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2023-01-01 to 2023-06-30$500.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-04-01 to 2023-06-30$502.0mus-gaap:NetIncomeLoss
Net income6 months2023-01-01 to 2023-06-30$874.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-04-01 to 2023-06-30$0.60us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2023-01-01 to 2023-06-30$1.05us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-04-01 to 2023-06-30$0.61us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-01-01 to 2023-06-30$1.05us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-04-01 to 2023-06-30831,300,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2023-01-01 to 2023-06-30832,100,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2023-01-01 to 2023-06-30$1.46bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2023-01-01 to 2023-06-30$347.0mus-gaap:PaymentsToAcquireProductiveAssets
Share repurchases6 months2023-01-01 to 2023-06-30$551.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2023-06-30$819.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-06-30$5.44bnus-gaap:AssetsCurrent
Total assetsAt period end2023-06-30$16.23bnus-gaap:Assets
Current liabilitiesAt period end2023-06-30$4.63bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-06-30$15.91bnus-gaap:Liabilities
Long-term debtAt period end2023-06-30$8.95bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2023-06-30$16.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2023-06-30−$64.0mus-gaap:StockholdersEquity
Shares outstandingAt period end2023-06-30826,691,529 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0000021665-23-000031. Last ingested by Listed: Nov 6, 2026, 16:45 ET. Listed shows no prices and gives no investment advice.